SCHEMBL14920868

SCHEMBL14920868

CCOC(=O)C1(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.37
POLB P06746 1/20 0.35
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
OPRD1 P41143 3/20 0.33
OPRK1 P41145 3/20 0.33
SLC22A1 O15245 1/20 0.33
SLC6A4 P31645 1/20 0.33
ADRA1A P35348 1/20 0.33
KCNH2 Q12809 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ATM Q13315 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 1/20 0.33
CYP4F2 P78329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7410851 0.93 SMN1; SMN2 (0.39) OPRM1POLBALDH1A1SMN1; SMN2NFKB1
SCHEMBL15074964 0.90 OPRM1 (0.47) OPRM1POLBOPRD1OPRK1SLC22A1
SCHEMBL18134201 0.85 ALDH1A1 (0.46) OPRM1POLBALDH1A1SMN1; SMN2OPRD1
SCHEMBL69496 0.85 ALDH1A1 (0.46) OPRM1POLBALDH1A1SMN1; SMN2OPRD1
SCHEMBL22931136 0.83 CYP4F2 (0.32) CYP4F2CYP4A11
SCHEMBL24183700 0.81 CYP4F2 (0.37) TSHRCYP4F2CYP4A11
SCHEMBL8493675 0.81 GAA (0.35) OPRM1POLBALDH1A1SMN1; SMN2NFKB1
SCHEMBL2206945 0.80 SMN1; SMN2 (0.46) POLBALDH1A1SMN1; SMN2TSHR
SCHEMBL6992779 0.78 USP2 (0.42) SMN1; SMN2TSHR
SCHEMBL16987661 0.78 DGAT1 (0.40) LMNAMEN1KMT2ACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145354-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2015-09-29 US disclosed
US-20150051199-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2015-02-19 US disclosed
EP-2773615-A1 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2014-09-10 EP disclosed
CN-104039766-A Pharmaceutical compounds ASTEX THERAPEUTICS LTD 2014-09-10 CN disclosed
WO-2013064543-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051199-A1 PHARMACEUTICAL COMPOUNDS NR1H4, HAVCR2, NR1H3 OPRM1 11/4885POLB 3322/4885ALDH1A1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.